Atwood & Palmer’s Biogen BIIB Stock Holding History

Atwood & Palmer’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08K	Sell	5 -7	-58%	-$1.34K	﹤0.01%	452
2026 Q1	$2.2K	Buy	12 +7	+140%	+$1.29K	﹤0.01%	437
2025 Q4	$880	Hold	5	–	–	﹤0.01%	466
2025 Q3	$701	Hold	5	–	–	﹤0.01%	468
2025 Q2	$628	Hold	5	–	–	﹤0.01%	493
2025 Q1	$685	Hold	5	–	–	﹤0.01%	418
2024 Q4	$765	Hold	5	–	–	﹤0.01%	445
2024 Q3	$970	Sell	5 -3	-38%	-$628	﹤0.01%	433
2024 Q2	$1.74K	Hold	8	–	–	﹤0.01%	403
2024 Q1	$1.62K	Sell	8 -41,588	-100%	-$9.74M	﹤0.01%	381
2023 Q4	$10.8M	Sell	41,596 -40	-0.1%	-$9.82K	0.87%	49
2023 Q3	$10.7M	Sell	41,636 -66	-0.2%	-$17.7K	0.94%	46
2023 Q2	$11.9M	Buy	41,702 +1,014	+2%	+$302K	1.06%	39
2023 Q1	$11.3M	Buy	40,688 +54	+0.1%	+$14.9K	1.06%	38
2022 Q4	$11.3M	Buy	40,634 +552	+1%	+$156K	1.02%	40
2022 Q3	$10.7M	Buy	40,082 +478	+1%	+$102K	1.06%	37
2022 Q2	$8.08M	Sell	39,604 -1,740	-4%	-$356K	0.79%	48
2022 Q1	$8.71M	Buy	41,344 +117	+0.3%	+$25.4K	0.75%	45
2021 Q4	$9.89M	Buy	41,227 +1,056	+3%	+$272K	0.83%	43
2021 Q3	$11.4M	Buy	40,171 +353	+0.9%	+$116K	1.01%	38
2021 Q2	$13.8M	Buy	39,818 +470	+1%	+$142K	1.24%	34
2021 Q1	$11M	Buy	39,348 +543	+1%	+$146K	1.06%	35
2020 Q4	$9.5M	Buy	38,805 +1,170	+3%	+$302K	1.02%	33
2020 Q3	$10.7M	Buy	37,635 +170	+0.5%	+$47.4K	1.34%	30
2020 Q2	$10M	Buy	37,465 +36,965	+7,393%	+$11.1M	1.35%	28
2020 Q1	$158K	Hold	500	–	–	0.02%	126
2019 Q4	$148K	Hold	500	–	–	0.02%	139
2019 Q3	$116K	Sell	500 -200	-29%	-$46.6K	0.02%	155
2019 Q2	$164K	Hold	700	–	–	0.02%	135
2019 Q1	$165K	Hold	700	–	–	0.02%	130
2018 Q4	$211K	Hold	700	–	–	0.03%	117
2018 Q3	$247K	Hold	700	–	–	0.03%	116
2018 Q2	$203K	Hold	700	–	–	0.03%	124
2018 Q1	$192K	Hold	700	–	–	0.03%	127
2017 Q4	$223K	Hold	700	–	–	0.03%	124
2017 Q3	$219K	Hold	700	–	–	0.03%	122
2017 Q2	$190K	Hold	700	–	–	0.03%	131
2017 Q1	$191K	Hold	700	–	–	0.03%	118
2016 Q4	$199K	Hold	700	–	–	0.04%	111
2016 Q3	$219K	Buy	+700	New	+$207K	0.04%	107

Other funds holding BIIB

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

ADEF

Adams Diversified Equity Fund Baltimore, Maryland $3.27B AUM 45.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Atwood & Palmer's BIIB Position: Q2 2026 in Review

Atwood & Palmer reduced its Biogen (BIIB) stake by 58% in Q2 2026, selling an estimated $1.34K and leaving 5 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #452.

Atwood & Palmer first reported a position in BIIB in Q3 2016 and has held it in 40 quarters since. The position peaked at $13.8M in Q2 2021. 269 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Atwood & Palmer held 5 shares of Biogen worth $1.08K as of Q2 2026.
Atwood & Palmer sold 7 Biogen shares in Q2 2026, an estimated $1.34K.
Biogen made up ﹤0.01% of Atwood & Palmer's portfolio in Q2 2026, its #452 holding.
Atwood & Palmer first reported a position in Biogen in Q3 2016 and has held it in 40 quarters since.
Atwood & Palmer's Biogen position peaked at $13.8M in Q2 2021.
269 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Atwood & Palmer's 13F filing for Q2 2026, filed 8 Jul 2026.